Current medical grade histopathological slides can only provide 2D images of partial biopsy for the interpretation by pathologists, which is thus difficult to quantify and standardize the diagnosis for evaluating whole picture of histopathological biopsy. We propose to develop a disruptive innovation technology “Automated 3D Histopathology Platform” for solving the problems. Our team innovates an original optical tissue clearing immersion with high-resolution of 3D image technology, using scanning/slicing by turns to control the depth of continuous automatic images, and digital suture parallel multi-stack images to obtain panoramic 3D digital images of a complete histopathological sample. Key technologies include: immersion high-resolution deep-clear imaging technology, rapid procedures for large-scale tissue, whole tissue image capture system, and big data quantitative analysis of standardized 3D image, by which detection in-depth and comparative analysis of normal and pathological organization can be achieved. Our team masters the critical opportunity during the initiative era of digital histopathology, and aims at developing global market of 3D digital histopathological industry with the main base and R&D center in Taiwan. This proposal is designed to establish a high-resolution 3D digital imaging-based business model, featuring medical testing and diagnostic services in combined with big data analysis. We will actively develop disruptive innovation 3D digital technology for histopathological image analysis and management applications, and Laboratory Developed Tests (LDT) in the globle market. Integration with Taiwan’s leading edge in information and communication technology industry, we will adopt characteristics of digital imaging data and develop software and database with comparative functions. Revolutionary impacts on histopathological analysis and intelligent therapeutic approach are anticipated. Our innovative team will take the leading opportunities of the medical industry, mastering the emerging digital histopathology to create output value for the country.